SCHEMBL20186913

SCHEMBL20186913

C=CC(=O)Nc1cccc(C)c1Nc1ncnc2c(C(=O)Nc3cccc4ccccc34)csc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.45
FYN P06241 1/20 0.45
CSF1R P07333 4/20 0.41
RAF1 P04049 3/20 0.41
BRAF P15056 3/20 0.41
DDR1 Q08345 3/20 0.41
DDR2 Q16832 3/20 0.41
ARAF P10398 1/20 0.41
FGFR4 P22455 8/20 0.41
FGFR1 P11362 4/20 0.40
EGFR P00533 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186959 0.85 FGFR4 (0.44) CSF1RRAF1BRAFDDR1DDR2
SCHEMBL20186911 0.84 FGFR4 (0.42) SRCCSF1RRAF1BRAFDDR1
SCHEMBL20186946 0.84 MAPK3 (0.44) CSF1RRAF1BRAFDDR1DDR2
SCHEMBL20186909 0.84 FGFR4 (0.41) CSF1RRAF1BRAFDDR1DDR2
SCHEMBL20186929 0.83 FGFR4 (0.54) RAF1BRAFFGFR4FGFR1
SCHEMBL20186914 0.83 FGFR4 (0.40) SRCCSF1RRAF1BRAFDDR1
SCHEMBL20186910 0.80 BMX (0.49) DDR1FGFR4FGFR1EGFRMEN1
SCHEMBL20186950 0.78 BMX (0.61) SRCCSF1RRAF1BRAFDDR1
SCHEMBL20186916 0.76 MAP3K7 (0.49) SRCFGFR4EGFR
SCHEMBL20186918 0.74 MAPK3 (0.46) SRCFYNEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US claimed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US claimed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-08-07 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148459-A1 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS CDK2, CDK2AP2, CDK2AP1 SRC 309/4885FYN 915/4885CSF1R 3614/4885
US-10040803-B2 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors CDK2, CDK2AP2, CDK2AP1 SRC 309/4885FYN 915/4885CSF1R 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.